Completed PHASE3 INTERVENTIONAL 1-arm NCT01400425

Potential of Florbetapir F 18 PET to Inform Clinical Diagnosis and Management of Patients With Progressive Cognitive Decline

Sponsor: Avid Radiopharmaceuticals

Conditions Progressive Cognitive Decline

Updated 6 times since 2017 Last updated: Mar 22, 2013 Started: Jul 31, 2011 Primary completion: Jul 31, 2012 Completion: Jul 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Progressive Cognitive Decline, this trial is completed. The trial is conducted by Avid Radiopharmaceuticals and has accumulated 6 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Jul 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Avid Radiopharmaceuticals

Data source: Avid Radiopharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Boulder, United States , Boynton Beach, United States , Clearwater, United States , Durham, United States , Fort Myers, United States , Greensboro, United States , Houston, United States , Las Vegas, United States , New York, United States , Patchogue, United States and 7 more locations